Animal Model Market

How big is Animal Model Market in 2026?

Demand is projected to expand at 6.1% CAGR from 2026 to 2036. Market value rises from USD 2 billion in 2025 to USD 2.12 billion in 2026 and USD 3.82 billion by 2036.

An animal model is useful when its biological characteristics address a defined research question, making species, genetic background and health status relevant to the scientific and commercial decision. Demand includes established models and more specialized work for academic, pharmaceutical and biotechnology programs, while the appropriate method depends on the purpose of the investigation rather than a general requirement to use animals in every study. [1][2][3][4] Mice and drug discovery retain substantial positions within the species and application classifications. At the same time, replacement, reduction and refinement influence study design, and US regulatory initiatives are expanding the use of suitable non-animal approaches. [1][2][3] Three-dimensional bioprinting provides one related route to human tissue models, although each approach needs to be evaluated for the question it is intended to answer. Suppliers consequently need to connect model availability with reproducible biological characteristics and appropriate support, while alternatives can change demand in selected applications. Through 2036, the market is expected to evolve around specialized research needs and the suitability of the evidence generated, with animal welfare and method selection remaining integral to the work. [1][2][3][4]

Key Market Trends & Insights

• Research customers are selecting models according to the biological question, making genetic characterization and health status relevant alongside the practical availability of animals.
• Replacement, reduction and refinement remain central to research design, creating demand for methods that improve scientific usefulness while reducing avoidable animal use. [2][3]
• FDA initiatives recognize non-animal approaches within nonclinical development, with the actual context of use and supporting evidence determining which method is appropriate. [1]

Regional Highlights

• US regulatory activity is expanding attention to non-animal methods, so animal-model demand needs to be considered alongside changing approaches to nonclinical evidence. [1]
• Germany and France operate within the European framework for animals used in science, which centers on replacement, reduction and refinement. [2]
• UK 3Rs resources and Japan's institutional guidance provide different local settings for research design and animal-care responsibilities. [3][4]

Market Size & Forecast

Table 1: Market Size and Forecast for Animal Model Market (USD billion and percentage), 2025 to 2036

Metric	Value
2025 market value	USD 2 billion
2026 market value	USD 2.12 billion
2036 market value	USD 3.82 billion
CAGR 2026 to 2036	6.1%
Revenue increase 2026 to 2036	USD 1.7 billion
Market expansion 2026 to 2036	1.80 times

The market is projected to rise from USD 2.12 billion in 2026 to USD 3.82 billion by 2036, at a CAGR of 6.1%. The outlook reflects specialized research requirements while allowing for the changing use of alternatives in selected applications. Biologics research is one relevant demand setting, but the appropriate preclinical method depends on the product and question within the relevant development and evidence pathway. [1][2][3]

How do scientific suitability and alternatives shape model demand?

The choice of a research model begins with the biological question and the information needed to answer it, while welfare principles influence how the study is designed. European and UK resources define replacement, reduction and refinement, and FDA's current initiatives recognize non-animal approaches without prescribing one method for every development program. Japan's guidance provides a further institutional context for work involving animals. [1][2][3][4]

Table 2: Industry evidence relevant to the animal model market

Indicator	Data point or observation	Market relevance	Source
Alternative methods	FDA recognizes NAMs alongside nonhuman in-vivo testing	Method suitability depends on the context and required evidence	[1]
European research framework	The Commission describes replacement, reduction and refinement	Study design includes scientific and welfare considerations	[2]
Institutional guidance	MEXT publishes animal-experimentation guidelines and implementation resources	Local research arrangements remain relevant to animal care	[4]

Analyst Perspective

"Animal model demand is expected to advance through precision research needs and stronger preclinical validation standards across drug pipelines."

- Anurag Sharma, Principal Consultant for Healthcare, FMI

How is the Animal Model Market segmented?

The market is segmented by Species, End User, Application, and Region.

The market is segmented by species into rats, mice, guinea pigs, monkeys, dogs, pigs, cats and other animals, with end users including academic and research institutions, pharmaceutical companies, biotechnology companies, contract research organizations and others. Basic and applied research and drug discovery or development form the application groups, while model selection depends on the biological question and the suitability of available methods.

Why do mice retain the larger species share?

The Mice segment is projected to account for 65.0% of species demand in 2026.

Table 3: Species Share for Animal Model Market (percentage share), 2026

Species	Estimated share (2026)
Mice	65.0%
Other species segments	35.0%
Total	100.0%

Table 4: Segment Position and Market Growth for Animal Model Market, 2026 to 2036

Metric	Value
Global CAGR (2026 to 2036)	6.1%
Profiled species segment	Mice

Mice have an established place in research programs that use defined strains and genetic characteristics to examine biological processes, creating a broad supply base for standardized and specialized models. The commercial requirement includes knowing which model is being supplied and whether its health and biological characteristics suit the planned investigation. This is a different purchasing task from selecting animals by species alone, because a particular genetic background or disease-related characteristic may determine whether the experiment can address its question. Replacement and reduction principles also remain relevant, so the segment's position does not establish that a mouse model is necessary for every program. [2][3] Demand reflects the research questions for which these models remain useful alongside the growing evaluation of other methods.

• Mice are projected to represent 65.0% of species demand in 2026, providing established strains and specialized genetic models for investigations requiring defined biological characteristics.
• Model identity, health status and the scientific question influence suitability, while replacement and reduction remain relevant to study design. [2][3]

Why does drug discovery and development hold the larger application share?

The Drug Discovery/Development segment is projected to account for 55.0% of application demand in 2026.

Table 5: Application Share for Animal Model Market (percentage share), 2026

Application	Estimated share (2026)
Drug Discovery/Development	55.0%
Basic and Applied Research	45.0%
Total	100.0%

Drug development programs need evidence about biological behavior before and alongside later clinical investigation, creating demand for research methods that address particular safety or disease questions. Animal models remain part of that methodological landscape, while FDA's current initiatives also recognize suitable non-animal approaches and leave method selection tied to the evidentiary task. [1] Preclinical CRO services can connect model-based investigations with the specialist work commissioned by pharmaceutical and biotechnology programs, giving sponsors access to study capabilities around the chosen method. Demand therefore involves model characterization and scientific relevance alongside availability. The segment's position follows the scale of development activity and specialist study requirements, with alternatives able to change the method mix where they provide suitable evidence for the question under investigation. [1][2][3]

• Drug Discovery/Development is projected to account for 55.0% of application demand in 2026, requiring characterized models and specialist studies suited to defined preclinical questions.
• Method selection depends on the question and supporting evidence, with appropriate alternatives able to reduce or replace animal use in defined contexts. [1][2][3]

What are the drivers, restraints, and opportunities in the Animal Model Market?

A model's value depends on how well its biological characteristics address the investigation, which keeps characterization and scientific support central to purchasing. Alternative methods can change demand in applications where they provide suitable evidence, alongside animal-care and study-design requirements. Suppliers have an opportunity to help customers select and use appropriate models, with reproducibility and a clear research purpose becoming more consequential than availability considered on its own. [1][2][3][4]

Driver

Disease research and development programs create demand for models with defined biological characteristics, particularly when an investigation needs a reproducible relationship between the model and the process being studied. Suppliers contribute characterized strains and expertise, while customers choose a method suited to the question. This requirement operates alongside replacement, reduction and refinement throughout the investigation. [2][3] Demand therefore depends on the usefulness of the evidence and the model's suitability, with animal and non-animal methods assessed for their actual scientific purpose. [1]

Restraint

Alternative methods can change demand where they provide suitable evidence for a particular question, while animal-care requirements and study-design responsibilities add practical conditions to the use of live models. FDA and European initiatives explicitly support reducing or replacing animal use in appropriate contexts. [1][2] A poorly matched model can also generate information that does not answer the intended question, limiting the value of the investigation. Suppliers consequently face a market in which biological relevance and characterization matter alongside availability and breeding capacity. [3]

Opportunity

Specialized model characterization and scientific support can help customers identify the biological attributes needed for an investigation, while study design determines how the resulting observations can be interpreted. Animal healthcare contributes to maintaining the health status required by a research program, giving ongoing observation and appropriate veterinary care a practical role in model supply. Providers can develop a more useful service around those characteristics and the scientific question, alongside suitable alternatives that may change the method required for a particular investigation. [1][2][3][4]

Which country CAGRs are profiled in the Animal Model Market?

Table 6: Country CAGR Comparison for Animal Model Market (CAGR percentage), 2026 to 2036

Country	CAGR	Forecast period
United States	7.5%	2026 to 2036
United Kingdom	5.9%	2026 to 2036
Germany	6.4%	2026 to 2036
France	6.3%	2026 to 2036
Japan	6.5%	2026 to 2036

Country-wise Analysis

United States Animal Model Market Outlook (2026 to 2036)

FDA's current non-animal-method initiatives make the US market a setting in which established research models and alternative approaches need to be assessed together. Its September 2026 terminology initiative recognizes NAMs as well as nonhuman in-vivo testing and explicitly does not prescribe one method or change evidentiary standards. [1] The US animal model market is projected to expand at a CAGR of 7.5% from 2026 to 2036. This outlook depends on specialized research demand rather than a universal animal-testing requirement. Pharmaceutical and biotechnology customers need a method suited to the product and biological question, while suppliers contribute characterized models and supporting knowledge. The commercial comparison therefore concerns the evidence a study can generate, with alternatives able to change the method selected for particular development tasks.

United Kingdom Animal Model Market Outlook (2026 to 2036)

The UK's NC3Rs provides a clear local focus on replacement, reduction and refinement, giving research teams a framework for examining whether an animal study can be avoided, improved or designed with fewer animals. [3] These principles affect the scientific task as well as welfare considerations, because the method needs to answer the intended question. The market is projected to grow at a CAGR of 5.9% from 2026 to 2036. Suppliers serving academic and pharmaceutical users therefore need to connect model characteristics with the planned investigation, rather than assume that established strains are suitable in every setting. Genetic identity and health status remain relevant to reproducibility, while available non-animal approaches need to be considered where they can provide the information required by the research program.

Germany Animal Model Market Outlook (2026 to 2036)

Germany's pharmaceutical and academic research base creates demand for defined models, while the European framework places replacement, reduction and refinement at the center of work involving animals. The Commission also describes activities supporting validation and acceptance of alternatives. [2] Germany's market is projected to expand at a CAGR of 6.4% from 2026 to 2036. The relevant purchasing decision consequently involves the model's biological suitability and the purpose of the study, not just the availability of a species. Specialized genetic models can serve particular research questions, while appropriate alternatives may change the method used for other tasks. This setting gives characterization and scientific support an important commercial role, with the supplier helping customers understand the model's attributes within a broader methodological choice.

France Animal Model Market Outlook (2026 to 2036)

French research demand includes pharmaceutical and academic programs that need defined biological models, with the market projected to grow at a CAGR of 6.3% from 2026 to 2036. Within the European framework, the scientific question is considered alongside replacement, reduction and refinement, while validation work supports the use of suitable alternatives. [2] A customer may need a specialized model for one investigation and a non-animal method for another, making the purpose of the study central to commercial demand. Suppliers therefore need consistent model identity and health characterization, while service requirements can include support for selecting the appropriate research attributes. This is a more specific purchasing task than ordering by species alone, with the usefulness of the eventual evidence determining whether the chosen model serves its intended role.

Japan Animal Model Market Outlook (2026 to 2036)

Japan's MEXT publishes fundamental guidance for animal experimentation and resources on institutional implementation, giving research organizations a documented local framework for work involving animals. [4] The market is projected to expand at a CAGR of 6.5% from 2026 to 2036, supported by pharmaceutical and academic research needs. Model choice still depends on the biological process being investigated, with defined genetic and health characteristics relevant to whether results can be interpreted consistently. Suppliers can support this requirement through characterized models and practical research knowledge, while the study team considers available methods and the intended use of the evidence. The institutional setting therefore connects animal care with scientific planning, rather than treating model supply as a separate transaction unrelated to the conditions of the research program.

Who are the notable companies in the Animal Model Market?

Charles River Laboratories; The Jackson Laboratory; Taconic Biosciences; genOway; Crown Bioscience

The participant field includes organizations supplying established strains, developers of specialized genetic models and providers combining models with preclinical services. These roles address different customer needs, because a laboratory purchasing a defined strain may require a different level of support from a program commissioning a specialized investigation. The useful comparison concerns model characteristics, reproducibility and the service needed to address the actual question, while the wider evaluation of alternatives can change the method mix. Scientific fit remains more informative than breeding scale considered on its own. [1][2][3][4]

Competitive Benchmarking: Animal Model Market

Table 7: Competitive positioning for the animal model market

Company	Positioning	Commercial distinction
Charles River Laboratories	Research models and associated preclinical services	Provides model supply and support across pharmaceutical and research programs.
The Jackson Laboratory	Defined mouse models and research support	Supplies characterized mouse-model resources for scientific investigations.
Taconic Biosciences	Rodent research models and model services	Supports standardized and specialized model requirements.
genOway	Genetically engineered research models	Develops models for defined biological and preclinical questions.
Crown Bioscience	Preclinical disease models and research services	Provides model-based services for pharmaceutical development.

Key Developments in the Animal Model Market

• FDA's September 2026 terminology initiative recognizes non-animal methods alongside nonhuman in-vivo testing, while the agency states that it does not prescribe a particular method or change evidentiary standards. [1]
• The European Commission adopted a roadmap for phasing out animal testing in chemical safety assessments in June 2026, a defined chemical-testing initiative within the broader 3Rs environment rather than a claim that all animal research has ended. [2]
• MEXT's animal-experimentation resources include an August 2026 institutional implementation survey, providing current information alongside its published fundamental guidance for research organizations. [4]

Key Players in the Animal Model Market

Research models and associated preclinical services

• Charles River Laboratories

Defined mouse models and research support

• The Jackson Laboratory

Rodent research models and model services

• Taconic Biosciences

Genetically engineered research models

• genOway

Preclinical disease models and research services

• Crown Bioscience

Animal Model Market - Report Scope

Table 8: Report Scope for Animal Model Market, 2026 to 2036

Coverage field	Report scope
Market	Animal Model Market
Historical reference	2025
Base year	2026
Forecast period	2026 to 2036
Currency and units	USD billion
Segmentation	Species, End User, Application
Geographic coverage	North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia & Pacific, Middle East and Africa
Country and market profiles	United States, United Kingdom, Germany, France, Japan
Representative companies	Charles River Laboratories; The Jackson Laboratory; Taconic Biosciences; genOway; Crown Bioscience

Animal Model Market - Research Methodology

Table 9: Research Methodology for Animal Model Market, 2026 edition

Method	Approach
Market definition	Research models are examined by species, biological characteristics, end user and application.
Scientific assessment	Model suitability is related to the question and information required by the investigation.
Segmentation	Species, end-user and application categories retain their separate roles.
Geographic assessment	Five country profiles relate projected demand to documented research and welfare frameworks.
Competitive assessment	Strain suppliers, specialized-model developers and preclinical service providers are distinguished.
Evidence review	Current official resources support method-selection, alternative-testing and institutional statements.

Animal Model Market by Segments

Animal Model Market segmented by Species:

• Rats
  • Mice
  • Guinea Pigs
  • Monkeys
  • Dogs
  • Pigs
  • Cats
  • Other Species

Animal Model Market segmented by End User:

• Academic & Research Institutions
  • Pharmaceutical Companies
  • Biotechnology Companies
  • Contract Research Organizations (CROs)
  • Other End Users

Animal Model Market segmented by Application:

• Basic and Applied Research
  • Drug Discovery/Development

Animal Model Market by Region

• North America
  • United States
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Chile
• Western Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Benelux
  • Nordics
• Eastern Europe
  • Poland
  • Czech Republic
  • Romania
  • Hungary
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia and New Zealand
• Middle East and Africa
  • GCC Countries
  • South Africa
  • Türkiye
  • Israel

Research Sources and Bibliography

• [1] US Food and Drug Administration. Accessed 15 October 2026. New Approach Methodologies
• [2] European Commission. Accessed 15 October 2026. Animals in science
• [3] NC3Rs. Accessed 15 October 2026. The 3Rs
• [4] Japan Ministry of Education, Culture, Sports, Science and Technology. Accessed 15 October 2026. Fundamental animal experimentation guidelines and implementation resources

This Report Answers

• How large is the animal model market in 2026?
• What is the outlook through 2036?
• Which species has the larger share?
• Which application leads demand?
• Do current initiatives require one method for every study?